The purpose of this study is to evaluate the safety and efficacy of AMX0035 in subjects with ALS.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study NCT 03127514.
Subjects with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, who are aged 80 years or less, have good breathing (FVC greater than 60%) and who have had weakness for less than 18 months.
June 01, 2018